摘要
目的综合定量评价索拉非尼治疗晚期肝细胞癌患者的疗效。方法检索中国生物医学文献数据库、中国学术期刊全文数据库、PubMed和Web of knowledge数据库,辅以手工检索和Google网络检索,以是否死亡为结局指标,采用优势比(OR)为效应指标,用倒方差的随机模型对符合条件的文献进行Meta分析。结果齐性检验的P=0.006,随机效应模型中的OR加权平均估计值为0.367,95%可信区间为(0.162,0.833),P=0.017,差别有统计学意义。结论索拉非尼治疗晚期肝细胞癌是有效的。
Objective To quantitative assess the effect of sorafenib in the treatment of patients with advanced hepatocellular carcinoma comprehensively.Methods Search was conducted through the following electronic databases：CNKI,Chinese Bio-medicine Database,Medline,PubMed,along with Google web search and hands search to identify all the relevant studies.Whether patients died or not is outcome variable and odds ratio（OR）is effect size.Eligible literatures were evaluated with meta-analysis by means of the random model of converse-variance method.Results The P value of Homogeneity test equals 0.006 and the weighted average value of OR in the random effect model is 0.367,95%CI（0.162,0.833）,P=0.017,suggesting the difference has statistically significant.Conclusion Sorafenib is effective in the treatment of advanced hepatocellular carcinoma.
出处
《中国卫生统计》
CSCD
北大核心
2010年第5期498-500,504,共4页
Chinese Journal of Health Statistics
关键词
索拉非尼
肝细胞癌
META分析
Sorafenib
Advanced hepatocellular carcinoma
Meta-analysis
